Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
schizophrenia
Biotech
Boehringer pays €25M for option to Sosei’s schizophrenia drug
Boehringer has secured an opportunity to beef up its schizophrenia portfolio courtesy of a €25 million ($27.3 million) deal with Sosei Heptares.
James Waldron
Mar 11, 2024 9:10am
Minerva's schizophrenia drug rejected by FDA for 2nd time
Feb 27, 2024 9:34am
Another company bid against BMS' $14B offer for Karuna
Jan 22, 2024 4:39pm
AbbVie’s pursuit of Cerevel was CEO Gonzalez's Christmas wish
Jan 7, 2024 8:44pm
Oryzon med fails to improve borderline personality disorder
Jan 7, 2024 4:17pm
UPDATE: Bristol Myers Squibb unwraps $14B deal for Karuna
Dec 22, 2023 7:32am